Los Angeles, CA—ChromaDex Corp announced in a press release that it has entered into a license and supply agreement with Nestlé Health Science (NHS).
The agreement, according to the company, gives NHS the exclusive right to include ChromaDex’s patented nicotinamide riboside ingredient, TRU NIAGEN, in NHS branded medical nutrition, and co-exclusive rights to include TRU NIAGEN in certain products within the consumer health category.
TRU NIAGEN has been shown in studies to elevate the coenzyme nicotinamide adenine dinucleotide (NAD) in humans, a metabolite involved in virtually every metabolic process in the body, according to ChromaDex.
“Nestlé Health Science is a blue chip global company whose expertise in consumer health products is matched by their exceptional science,” Rob Fried, CEO of ChromaDex, said in the release. “We believe Nestlé Health Science’s portfolio with TRU NIAGEN will substantially advance their already strong market position. Importantly, this partnership will help educate people on the importance of elevating NAD levels. We are proud to be in business with Nestlé and look forward to a long, mutually beneficial relationship.”
Greg Behar, CEO of NHS, said in the release, “We are quite impressed with the science supporting TRU NIAGEN, and the excellent work done by the team of professionals at ChromaDex. We see this innovation as an important element of our product portfolio. We are confident that TRU NIAGEN combined with our products will provide consumers the opportunity to improve the health of their cells with the power of nutrition.”
The agreement, according to the release, states that NHS will make an upfront payment of $4 million, after which ChromaDex will receive milestone payments related to the sale of TRU NIAGEN and tiered royalties.